Scarica l'app Stockscreener
6.04
0.00%
0.00
Dopo l'orario di chiusura:
6.04
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
XERS Technical Analysis & Stock Price Forecast - Intellectia AI
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees - geneonline.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Insider Sell: James Brady Sells Shares of Xeris Biopharma Holdin - GuruFocus
Brady sells Xeris Biopharma (XERS) shares worth $60,035 By Investing.com - au.investing.com
Brady sells Xeris Biopharma (XERS) shares worth $60,035 - Investing.com
Xeris Biopharma (XERS) director sells 10,834 shares in Rule 10b5-1 trades - Stock Titan
XERS Stock Price, Quote & Chart | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aug Macro: Will Xeris Biopharma Holdings Inc stock recover after earningsEntry Point & AI Enhanced Trading Alerts - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard (XERS) disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares - Stock Titan
Revenue per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4%What's Next? - MarketBeat
Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS
Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc. - MarketBeat
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - simplywall.st
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xeris Pharmaceuticals Q2 2025 Earnings Preview - MSN
Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo
Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure - Markets Mojo
Why Is CORT Stock Falling Today? - Stocktwits
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings - MarketBeat
Xeris Biopharma (XERS) officer exercises options, lifts share holdings - Stock Titan
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):